Verifying the Vaccine

Chicago - As patient accrual to phase III trials of Canvaxin therapeutic polyvalent cancer vaccine nears the 1,000-mark, a randomized phase II trial of the vaccine was reported at the annual meeting of the American Society of Clinical Oncology. The trial used an immunostimulant to enhance the antibody response to a tumor-associated antigen (TA90) found on melanoma cells.